Corvus Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Für Corvus Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 20.2% bzw. 67.4% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 18.6% pro Jahr steigen soll.
Wichtige Informationen
20.2%
Wachstumsrate der Gewinne
18.57%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.2% |
| Wachstumsrate der Einnahmen | 67.4% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 15 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Seeking Alpha • Apr 08
Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success
Summary Corvus Pharmaceuticals is built on ITK inhibition, showing early promising data in both PTCL and atopic dermatitis. CRVS’s soquelitinib demonstrates superior mPFS and OS in PTCL versus historical controls, but data is early and from small cohorts. The current $1.24B valuation fully prices in success for both PTCL and AD, despite only early-stage clinical validation. I rate CRVS a sell at current prices due to market enthusiasm outpacing clinical and commercial proof. Read the full article on Seeking Alpha
Neues Narrativ • Apr 02
Multiple Trial And Dilution Risks Will Shape Future Immunology Upside Potential
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals focuses on developing soquelitinib, a selective ITK inhibitor, for immune mediated diseases and cancers. What are the underlying business or industry changes driving this perspective?
Neues Narrativ • Mar 19
Late Stage ITK Inhibitor Franchise Will Transform Immunology Pipeline Over The Long Term
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, a selective ITK inhibitor, for cancers and immune inflammatory diseases. What are the underlying business or industry changes driving this perspective?
Neues Narrativ • Mar 05
Targeted Immunology Pipeline Will Position This Biotech For Multiple Long Term Catalysts
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, an oral ITK inhibitor, for immune and inflammatory diseases and T cell lymphomas. What are the underlying business or industry changes driving this perspective?Analyseartikel • Nov 01
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Aug 19
Is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Trading At A 49% Discount?
Key Insights Corvus Pharmaceuticals' estimated fair value is US$10.34 based on 2 Stage Free Cash Flow to Equity Current...Analyseartikel • Jul 15
Corvus Pharmaceuticals (NASDAQ:CRVS) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Corvus...Seeking Alpha • Mar 28
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Summary Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments. As for Soquelitinib’s early AD results, I believe they were mostly positive, but they were based on limited data of just 28 days and 19 patients. Unfortunately, while Corvus' pipeline progress has been solid, they’re now running into dilution risks due to their short cash runway. Hence, I believe CRVS stock is a “Hold” now. Read the full article on Seeking AlphaSeeking Alpha • Mar 03
Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance
Summary Corvus Pharmaceuticals' lead asset, Soquelitinib, shows promising early data in treating peripheral T cell lymphoma, solid tumors, and atopic dermatitis. Despite competitive clinical data, Corvus faces significant financial risks with limited cash reserves and a small, highly differentiated PTCL market. The company has a market cap of $259 million and a cash runway of approximately six quarters, raising concerns about funding future trials and commercialization. Given the financial constraints and competitive landscape, I recommend staying on the sidelines for now. Read the full article on Seeking AlphaAnalyseartikel • Jan 13
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Corvus...Seeking Alpha • Dec 18
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Summary Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders. The company received a $12.7 million cash infusion from warrant exercises, bolstering its financial position and future development. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Corvus Pharmaceuticals: The Market Likes The Story
Summary Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked off a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus, or is some profit taking on the horizon? An analysis around Corvus Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Summary Corvus Pharmaceuticals is advancing soquelitinib, an ITK inhibitor, for peripheral T-cell lymphoma with a Phase 3 trial expected to start soon. Soquelitinib has shown promising Phase 1 data, particularly in patients with fewer prior therapies, but results in heavily pretreated patients are less encouraging. The drug's novel mechanism targets T-cell signaling to promote antitumor immunity, differentiating it from other treatments in PTCL. While soquelitinib's potential in PTCL is notable, the stock is best rated as a "hold" due to high uncertainty and the need for more conclusive clinical data. Read the full article on Seeking AlphaAnalyseartikel • Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Corvus...Analyseartikel • Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analyseartikel • May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Sep 26
Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Clinical-stage biopharma Corvus Pharmaceuticals (NASDAQ:CRVS) on Monday said an investigational new drug application to start a phase 1/1b trial of monoclonal antibody mupadolimab had been approved by China's drug regulator. The study was approved by the Center for Drug Evaluation of the China National Medical Products Administration, and will be conducted by Angel Pharmaceuticals, CRVS' partner in the Asian country. Mupadolimab is being evaluated for the treatment of patients with relapsed refractory non-small cell lung cancer and head and neck squamous cell cancers. Angel Pharma, a privately-held biopharma, was co-founded by CRVS to develop its pipeline in greater China. Angel Pharma licensed the rights from CRVS to develop, make and commercialize mupadolimab in greater China, Corvus (CRVS) said in a statement. CRVS stock +5% to $0.76 after hours.Analyseartikel • Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analyseartikel • Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analyseartikel • Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Dec 10
Checking In On Corvus Pharmaceuticals
Today, we look at Corvus Pharmaceuticals, a company that has multiple candidates in development. The stock has had a roller coaster ride so far in 2021. A full investment analysis is presented in the paragraphs below.Seeking Alpha • Sep 22
Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Corvus stock has made spectacular gains across the past week, rising from a price of $2.3 to $8.5 - a 270% gain. Last week, AstraZeneca's Oleclumab - an anti-CD73 therapy - substantially improved the risk of death in combo with IMFINZI in NSCLC. Corvus' Mupadolimab is an anti-CD73 monoclonal antibody and hopes are high that it can show similar efficacy to Oleclumab. Corvus recently discontinued the development of Mupadolimab as a COVID therapy and resumed trials of the drug in head and neck cancer. Data from that trial, and an expansion cohort in combo with Merck's Keytruda, ought to read out this year - a potentially exciting catalyst. Corvus deserves its recent uplift, in my view, but still has much to prove.Analyseartikel • Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analyseartikel • Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Investors who take an interest in Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) should definitely note that the...Analyseartikel • Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Every investor in Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) should be aware of the most powerful shareholder groups...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 40 | -72 | -80 | -94 | 4 |
| 12/31/2027 | 6 | -82 | -85 | -87 | 4 |
| 12/31/2026 | N/A | -64 | -63 | -72 | 4 |
| 3/31/2026 | N/A | -44 | -35 | -35 | N/A |
| 12/31/2025 | N/A | -15 | -33 | -33 | N/A |
| 9/30/2025 | N/A | -15 | -32 | -32 | N/A |
| 6/30/2025 | N/A | -45 | -29 | -29 | N/A |
| 3/31/2025 | N/A | -41 | -29 | -29 | N/A |
| 12/31/2024 | N/A | -62 | -25 | -25 | N/A |
| 9/30/2024 | N/A | -57 | -22 | -22 | N/A |
| 6/30/2024 | N/A | -23 | -21 | -21 | N/A |
| 3/31/2024 | N/A | -25 | -21 | -21 | N/A |
| 12/31/2023 | N/A | -27 | -24 | -24 | N/A |
| 9/30/2023 | N/A | -30 | -26 | -26 | N/A |
| 6/30/2023 | N/A | -39 | -28 | -28 | N/A |
| 3/31/2023 | N/A | -41 | -29 | -29 | N/A |
| 12/31/2022 | N/A | -41 | -27 | -27 | N/A |
| 9/30/2022 | N/A | -41 | -27 | -26 | N/A |
| 6/30/2022 | N/A | -37 | -28 | -28 | N/A |
| 3/31/2022 | N/A | -40 | -34 | -34 | N/A |
| 12/31/2021 | N/A | -43 | -37 | -37 | N/A |
| 9/30/2021 | N/A | -7 | -38 | -38 | N/A |
| 6/30/2021 | N/A | -6 | -37 | -37 | N/A |
| 3/31/2021 | N/A | -5 | -34 | -34 | N/A |
| 12/31/2020 | N/A | -6 | -35 | -35 | N/A |
| 9/30/2020 | N/A | -44 | -35 | -35 | N/A |
| 6/30/2020 | N/A | -46 | -38 | -38 | N/A |
| 3/31/2020 | N/A | -48 | -38 | -38 | N/A |
| 12/31/2019 | N/A | -47 | N/A | -37 | N/A |
| 9/30/2019 | N/A | -46 | N/A | -37 | N/A |
| 6/30/2019 | N/A | -46 | N/A | -37 | N/A |
| 3/31/2019 | N/A | -44 | N/A | -39 | N/A |
| 12/31/2018 | N/A | -47 | N/A | -41 | N/A |
| 9/30/2018 | N/A | -48 | N/A | -44 | N/A |
| 6/30/2018 | N/A | -51 | N/A | -44 | N/A |
| 3/31/2018 | N/A | -54 | N/A | -45 | N/A |
| 12/31/2017 | N/A | -56 | N/A | -46 | N/A |
| 9/30/2017 | N/A | -55 | N/A | -45 | N/A |
| 6/30/2017 | N/A | -52 | N/A | -41 | N/A |
| 3/31/2017 | N/A | -46 | N/A | -35 | N/A |
| 12/31/2016 | N/A | -36 | N/A | -28 | N/A |
| 9/30/2016 | N/A | -31 | N/A | -22 | N/A |
| 6/30/2016 | N/A | -24 | N/A | -19 | N/A |
| 3/31/2016 | N/A | -36 | N/A | -15 | N/A |
| 12/31/2015 | N/A | -31 | N/A | -11 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CRVS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: CRVS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: CRVS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: CRVSDie Einnahmen des Unternehmens (67.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: CRVSDie Einnahmen des Unternehmens (67.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CRVS in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/18 01:48 |
| Aktienkurs zum Tagesende | 2026/05/18 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Corvus Pharmaceuticals, Inc. wird von 13 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Etzer Darout | Barclays |
| Dane Leone | BTIG |
| Li Wang Watsek | Cantor Fitzgerald & Co. |